Skip to main content

Table 1 Characteristics of study subjects and healthy volunteers.

From: Eotaxin-1 in exhaled breath condensate of stable and unstable asthma patients.

Characteristics Dimension Healthy volunteers Steroid naïve asthma Stable ICS-treated asthma Unstable ICS- treated asthma
Number of patients   12 14 16 16
Sex F/M 6/6 8/6 9/7 10/6
Age Years 25.40 ± 5.20 25.00 ± 6.30 39.50 ± 10.70 45.80 ± 7.30
Duration of symptoms Years   2.71 ± 1.08 10.80 ± 6.20*Δ 17.06 ± 6.50*+
Baseline FEV1 % pred 102.50 ± 9.1 89.20 ± 12.00 Δ 80.80 ± 7.10 Δ 51.50 ± 11.70*+
FEV1/FVC ratio % 86 ± 7 73 ± 8 64 ± 10 56 ± 12
Serum total IgE concentration kU/L 61.08 ± 25.50* 248.4 ± 202.3 232.5 ± 79.0 318.0 ± 98.0
Blood eosinophil count cells/mm3 56 ± 22* 212 ± 88 281 ± 73 302 ± 95
FENO ppB 15.80 ± 5.06* 75.21 ± 37.13+ 39.40 ± 12.50*Δ 64.70 ± 25.04+
Eotaxin-1 (EBC) pg/ml 6.24 ± 0.70* 9.70 ± 1.70Δ 10.45 ± 2.00Δ 17.97 ± 3.60*+
ECP (serum) μg/l 3.87 ± 0.81* 13.21 ± 4.56 12.80 ± 3.50 Δ 21.90 ± 8.40*+
ICS μg/day    359 ± 128 1078 ± 269
Positive SPT      
mite/cat/moulds    14/2/3 14/4/4 15/4/6
  1. Data are presented as medians (ranges)
  2. FEV1- forced expiratory volume in one second
  3. * Values significantly different from patients with steroid-naïve asthma, p < 0.05
  4. + Values significantly different from patients with stable, ICS-treated asthma, p < 0.05
  5. Δ Values significantly different from patients with unstable, ICS-treated asthma, p < 0.05
  6. ICS - inhaled corticosteroids (Fluticasone propionate equivalent)
  7. SPT - skin prick tests (number of patients)